This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome management. Adult patients aged 18-80 years with cardiovascular, kidney, and/or metabolic diseases or key data for CKM phenotyping will be enrolled at the First Affiliated Hospital of Fujian Medical University. The study integrates retrospective data entry and prospective follow-up, including clinical records, laboratory tests, medications, electrocardiography, echocardiography, vascular function assessment, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing data. The primary outcome is the first occurrence of a cardiorenal composite endpoint. Participants will be followed for up to 5 years through active annual follow-up and passive monthly data updates to support risk stratification, real-world evidence generation, and CKM management pathway optimization.
This study is a single-center CKM patient registry with retrospective data entry and prospective lifecycle follow-up. A patient-centered master index will be established primarily on the basis of hospitalization identifiers to integrate multi-source hospital data, including discharge records, diagnoses, laboratory testing, medications, electrocardiography, echocardiography, baPWV/ABI, carotid ultrasound, abdominal ultrasound, bone density, coronary CTA and post-processing metrics, and clinical outcome events. A structured longitudinal database will be created to support standardized phenotyping, event adjudication, and repeat-assessment tracking. The primary objective is to build a dynamic registry platform for CKM-related inpatients and to support long-term follow-up, outcome surveillance, risk stratification, and real-world evidence generation. The study is planned for 5 years, from March 1, 2026 to February 28, 2031, with annual active follow-up and monthly passive data updates. Major outcomes include a time-to-first cardiorenal composite endpoint, all-cause mortality, 3-point major adverse cardiovascular events, heart failure hospitalization or cardiovascular death, and additional pre-specified cardiovascular, renal, metabolic, oncologic, cognitive, and imaging progression outcomes.
Study Type
OBSERVATIONAL
Enrollment
8,000
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
RECRUITINGFirst occurrence of a cardiorenal composite endpoint
Time to first occurrence of cardiovascular death or kidney disease progression, defined as sustained decline in eGFR of at least 40% from baseline, sustained eGFR below 15 mL/min/1.73 m², initiation of maintenance dialysis, kidney transplantation, or renal death.
Time frame: Up to 5 years from enrollment
All-cause mortality
Time to death from any cause during follow-up.
Time frame: Up to 5 years from enrollment
3-point major adverse cardiovascular events (3-point MACE)
Time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal ischemic stroke.
Time frame: Up to 5 years from enrollment
First hospitalization for heart failure or cardiovascular death
Time to first hospitalization for heart failure or cardiovascular death during follow-up.
Time frame: Up to 5 years from enrollment.
Nonfatal Myocardial Infarction
First occurrence of nonfatal myocardial infarction during follow-up.
Time frame: Up to 5 years from enrollment
Nonfatal Ischemic Stroke
First occurrence of nonfatal ischemic stroke during follow-up.
Time frame: Up to 5 years from enrollment
Incident Atrial Fibrillation
New-onset atrial fibrillation among participants without a history of atrial fibrillation at baseline, confirmed by 12-lead electrocardiography, Holter monitoring, or inpatient/outpatient clinical diagnosis during follow-up.
Time frame: Up to 5 years from enrollment
Coronary Revascularization
First occurrence of coronary revascularization, including percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), during follow-up.
Time frame: Up to 5 years from enrollment
Aortic Disease Intervention
First occurrence of endovascular or surgical intervention for aortic dissection, aortic aneurysm, penetrating aortic ulcer, or other aortic diseases during follow-up.
Time frame: Up to 5 years from enrollment
Peripheral Vascular Events
First occurrence of peripheral vascular events, including acute limb ischemia, peripheral arterial revascularization, or major amputation due to vascular causes.
Time frame: From enrollment until the date of first documented peripheral vascular event, death, loss to follow-up, or end of study, whichever came first, assessed up to 5 years.
Incident Diabetes Mellitus
New-onset diabetes mellitus among participants without diabetes at baseline, defined as a new clinical diagnosis of diabetes, initiation of glucose-lowering therapy, or laboratory evidence meeting diagnostic criteria during follow-up.
Time frame: Up to 5 years from enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.